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ABSTRACT
This cross-sectional study sought to estimate the direct medical cost of Lassa fever treatment on patients in South-South 
Nigeria. All the 73 confirmed Lassa fever cases admitted in the isolation ward of the Institute Of Lassa Fever Research and 
Control, Irrua Specialist Teaching Hospital (ISTH) Irrua, in Edo State, Nigeria, between May 2015 and May 2016 were 
studied. A checklist was used to collect data on the socio-demographic characteristics and medical cost incurred by the 
patients. Data entry and analysis was done using SPSS version 20. The average total direct cost for Lassa fever treatment 
was N86,802.63 per patient for the subsidized treatment and N205,558.99 per patient for the unsubsidized treatment. 
Medications accounted for the highest unsubsidized payments (N86,929.55; 42.10%) while hospital care accounted for the 
highest cost component of he subsidized payments (N19,756.51; 22.76%). Up to 84.28% of medication and 70.8% of 
investigations was subsidized making a total of 57.77% subsidy in the average total payments per patient. For an average 
Nigerian, direct cost of treatment of Lassa fever is still expensive despite subsidy in medications and investigations. 
Therefore efforts geared towards reducing the economic burden of Lassa fever on patients and their families are advocated.
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INTRODUCTION
Healthcare expenditures often present a considerable challenge to the economic well-being of patients and households 
especially in low economic resource countries like Nigeria.(Leive and Xu, 2008). This can increase a household’s 
susceptibility to impoverishment (Chuma et al., 2007; Whitehead et al., 2001). The World Health Organization (WHO) 
estimated that households that spend 40% or more of their non-food expenditure on treatment are most likely to be 
impoverished (WHO, 2000). To this effect, the poor are likely to be the most affected, because they spend larger 
proportions of their income than the wealthier groups when they seek care (Leighton and Foster, 1993).
Lassa fever is a severe and often fatal hemorrhagic illness caused by Lassa virus (Frame et al., 1970). There have been 
countless outbreaks of various magnitude and severity across West Africa. Estimates of annual incidences of Lassa fever 
across this region reach as high as 300,000 infections and 5,000 deaths annually (Ogbu et al., 2007). Primarily, humans 
become infected from contact with urine and droppings of infected rodents of the genus mastomys. Transmission from 
person to person has also been established, presenting a challenge for health care workers. Other possible routes include 
inhalation of infective aerosols and transmission via sex, transplacental, and breast milk (Fisher-Hoch, et al. 1995;
Adewuyi et al., 2009; Cummins et al., 1990; Joel and Segel, 1990)
Lassa virus is easily isolated from the blood or serum during the febrile phase of the disease up to 14 or more days after 
onset, using ELISA (Enzyme-Linked Immunosorbent Assay) which detects IgM and IgG antibodies as well as Lassa 
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antigen.  Reverse transcriptase polymerase chain reaction test (RT-PCR) is also a sensitive test for Lassa virus (Asogun et 
al., 2012).All persons suspected of Lassa fever infection should be admitted to isolation facilities and their body fluids and 
excreta properly disposed (Adewuyi et al., 2009). Treatment is both specific with use of ribavirin and supportive which 
consist of maintenance of appropriate fluid and electrolyte balance, oxygenation and blood pressure, as well as treatment of 
any other complicating infection (Frame et al., 1970). 
Lassa fever like any other hemorrhagic fever can be adequately prevented and controlled by general public awareness, 
health education on Lassa fever, rodents control, food hygiene etc. No vaccine against Lassa fever is currently available 
though development is underway. (Correia et al., 2014). However due to scarce resources to diagnose the illness as well as 
inadequate surveillance, many cases remain unaccounted for. The disease has had considerable impact in endemic regions 
of West Africa (Peters et al., 2002).
Burden-of-illness studies (which are sometimes known as Cost-of-illness [COI] studies) analyze the total costs incurred 
due to a specific disease or health condition (WHO, 2015). This requires recognizing, identifying, listing, measuring and 
valuing the costs generated by an illness (Asian Development Bank, 2012). Direct economic costs of disease are those 
generated by the resources used in treating or coping with a disease, including expenditures for medical care and the
treatment of the illness (hospital care, physician services, nursing home care, drugs and other medical needs), borne by the 
healthcare system, community and family in directly addressing the problem. There are other indirect costs such as man 
hour loss and grief. However, some of these cannot be quantified directly in monetary terms (Federal Ministry of Health, 
2003; WHO, 2005). 
Direct cost of Lassa fever entails cost  incurred in obtaining a hospital card, investigations (Lassa polymerase chain 
reaction PCR, full blood count FBC, erythrocyte sedimentation rate ESR, electrolyte urea and creatinine E/U/Cr, malaria 
parasite test MP, liver function test LFT, serum protein, urinalysis etc), hospitalization, treatment which include drugs such 
as ribavirin, antibiotics, omeprazole, vitamins etc, blood transfusion, dialysis, medical supplies which include intravenous 
fluids, cannullae, syringes, sterile gloves, catheters, plaster etc and follow up visits.  Lassa fever carries a high degree of 
mortality and morbidity like other infectious diseases and these can be prevented by effective methods thus reducing the 
burden of the disease. Although part of Lassa fever treatment is being subsidized, bulk of the treatment is paid by patients 
out of pocket, thus still a burden to them. 
Out-of-pocket (OOP) expenditure on healthcare including treatment of Lassa fever imposes a significant burden on 
households (Essue et al., 2015; Atella et al., 2015; Wang, 2015) and is a major concern (Barros and Bertoldi, 2008; 
O'Donnell et al., 2008). This can lead to poor health seeking behaviours and inequity (WHO, 2012; Goudge et al., 2009; 
Wagstaff and van Doorsaler, 2000). Despite the paucity of data on the direct economic cost of Lassa fever, studies on other 
common endemic diseases have been carried out. A cross-sectional survey was conducted on the resource utilization 
pattern and cost of tuberculosis treatment from the provider and patient perspectives in the state of Penang, Malaysia in 
2010/2011 (Muhammad et al., 2014). The average provider sector cost was MYR 992.34 (median = MYR 891.55) (USD 
325.35 per patient).  In a cross-sectional study conducted in urban and rural areas of Magway, Myanmar, the mean of 
health expenditures per year was US$419 in the urban areas and US$79 in the rural areas (Inn et al., 2015). A cross-
sectional descriptive study on the Health care seeking patterns and determinants of out-of-pocket expenditure for Malaria 
for the children under-five in Uganda in 2009, a total cost of $7.26 in urban areas and $3.39 in rural areas was incurred in 
the treatment of malaria (Juliet et al., 2013). In a cross-sectional study conducted in Asa Local Government Area of Kwara 
State, Nigeria 2013, it costs an average of about ₦224 to treat malaria using self-medication compared to ₦326 for 
herbalist/spiritualist and ₦1,833 for clinic/hospital when admission is involved, while clinic/hospital treatment without 
admission costs about ₦1,361 (Olalekan et al., 2013).  
In another cross-sectional study conducted in Achi and Oji-river rural communities in Enugu State, Southeast Nigeria in 
2015. The average expenditure to treat malaria was $22.9, which was all incurred through out-of- pocket payments (Enyi et 
al., 2015). This was comparable to a study in Anambra and Enugu in southeast Nigeria, 2013 where the total treatment cost 
for each person for Typhoid,  Malaria, Diarrhea and others ranged from US$7.6 per month in the rural community of 
Amansea to US$25.6 per month in the urban community of Uwani (Oforbuike et al., 2013). It is also somewhat similar to 
the study on the Costs of Illness, Payment and Coping Strategies to Different Population Groups conducted among the 
Igbo-speaking tribe of Anambra and Enugu states in Southeast Nigeria in 2012 where the total cost of treatment for malaria 
was  2,819.9 Naira ($20 US) per person (Ogochukwu. et al., 2012). Other studies on cost of healthcare include a cross 
sectional study carried out in Bangladesh, on Coping strategies for financial burdens in families with childhood pneumonia 
in 2010, the median total out of pocket expenditure for patients interviewed was US$110 (Nadia et al., 2010).
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The study conducted in Orissa one of the poorest states of India, in 2012 on Hardship financing of healthcare among rural 
poor in Orissa, India revealed that 38.6% of health expenditure was spent on hospitalization, 24.5% was spent on 
maternity, 23.1% was spent on outpatient care and 24.9% was spent on other health events (Erika et al., 2012). In 
2003/2004, Villagers in rural Cambodia reported spending on average US$34.50 and up to US$150 for a single episode of 
dengue, with those not granted a fee exemption spending a mean of US$49.29 (range US$25–150) at a public facility and a 
mean expenditure of US$34.60 (range US$8.75–50.00) at a private practice (Sokrin and Lenore, 2008)..
As with the disease conditions studied above, Lassa fever also had an economic impact on the pocket of the victims but the 
cost is yet to be quantified in a scientific study. This study therefore sought to estimate the direct cost of Lassa fever illness 
on patients in south-south Nigeria where the disease is now endemic. In this regard, the study will provide a monetary 
estimate for the economic burden of Lassa fever and estimates the amount that could potentially be saved or gained if the 
disease were to be prevented or eradicated. Information obtained from this study will also help make informed choices in 
resource allocation by estimating resource consequences of health problems and a need for an increase in health sector 
investment to expand access to preventive and curative health services. This study can therefore help to focus society's 
attention on health and Lassa fever treatment leading to intervention from concerned authorities to ameliorate the medical 
cost to patients, economic hardship and improved well-being. 
METHODOLOGY
Study area: This study was be carried out in the Institute Of Lassa Fever Research And Control, Irrua Specialist Teaching 
Hospital (ISTH) Irrua, in Edo State, Nigeria. The institute was founded in January 2007 by the Board of Management of 
ISTH, following a proposal for its establishment made by the Chief Medical Director through the Hospital Management 
Committee to the board. The Institutes’ strategic location along the Benin-Abuja expressway in Irrua, the headquarters of 
Esan Central Senatorial District, enables it to serve the Central and Northern Senatorial Districts of Edo State, as well as 
parts of the Southern-Senatorial District. In addition, it also receives patients from the neighboring states of Delta, Kogi, 
Ondo and the country at large.52 The Institute Of Lassa Fever Research And Control is dedicated to the attainment of 
excellence in the control of Lassa fever, is the first of its kind in Nigeria and indeed the West Africa sub region36.
Study design/Study population: This was a cross-sectional study. The study subjects were confirmed cases of Lassa fever 
admitted between May 2015 and May 2016 into the Institute Of Lassa Fever Research And Control.
Inclusion and Exclusion criteria: Confirmed Lassa fever cases were included in this study, while Lassa fever patients 
who had other co-morbidities unrelated to Lassa fever were excluded.
Ethical consideration: An approval was obtained from the ISTH ethical committee. A Collaborative Institutional Training 
Initiative (CITI) program on good clinical practice and National ethics code was completed and certificates awarded.
Duration of study: A total population survey was done for Lassa fever patients seen from May 2015 to May 2016. 
Study Instrument: A checklist comprised of 2 sections.  Section A: Socio demographic data and Section B: Direct 
medical cost which include hospital care cost, cost of investigations, cost of medications, cost of intravenous fluids 
amongst others.
Collection of data: A checklist was developed and used to obtain information on the cost of treatment of Lassa fever from:   
Case notes of confirmed Lassa fever patients admitted to the Institute Of Lassa Fever Research And Control, ISTH. 
Institute Of Lassa Fever Research And Control, General laboratory, Accounting,  Pharmacy, Hospital catering and 
Radiology departments, ISTH.
Measurement of variables: The variables of interest include; total direct cost, average costs and pattern of cost. The total 
direct cost includes the sum of all the cost incurred in the treatment of Lassa fever. This included cost of hospital care, 
investigations, medications, fluids and other treatments.                         
The average cost was measured as:      
Total medical cost       
Total number of patients
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The pattern of cost was expressed as the average amount spent on each aspect of care: drugs, investigations, admissions etc 
and expressed in proportions and percentages. 
Table 1:  Socio-demographic characteristics of the patients










































No formal education 4 5.5
Total 73 100
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Data analysis: Continuous variables are described using mean and standard deviations, median and quartiles. Categorical 
variables were expressed in proportions and frequencies and data summarized using bar charts, pie charts and tables. Costs 
for each component were multiplied with the appropriate number. For drugs and saline, the unit cost was multiplied by the 
dosage number. Hospital stay, utilities, feeding and nursing costs in each day was multiplied by the total hospital days. 
Oxygen, dialysis and investigations unit costs were multiplies by the number of times they were administered or required. 
Different medical supplies such as saline sets face masks, glove packs, nasogastric tubes, catheters costs etc. were usually a 
one-time cost.  Out of pocket payments were defined as all payments made by the patient in the treatment of Lassa fever. 
The IBM statistical package for social sciences (SPSS) software version 20 was used for data entry and analysis. Data 
cleaning was conducted so as to take hold of data inconsistencies and other errors. Validity of data was certified by double 
checking entries for errors. Relevant frequency distribution tables and summary indices were generated such as mean for 
continuous variables.  
RESULTS
Social demographic characteristic:
Majority of the patients were less than 50years of age (89%) with a mean age of 32.8±3.5; married (61.6%) and Christians 
(83.6%). The gender distribution was in equal proportions. On education, 39.7% had attained tertiary education, 34.2% 
secondary and 26% was a combination of those who had only primary education and those that had no formal education.  
Students and individuals engaged in business ventures/traders constituted 27.4% and 26% of the patients respectively. 
Other occupations were professionals (9.6%), farmers (5.5%), artisans (5.5%) and drivers, motorcyclists, hair stylists etc. 
accounted for 26% of the patients (Table 1). 
Total and average direct medical cost of the treatment of Lassa fever:
The median total direct medical cost for the treatment of Lassa fever was N80, 704.00. The highest total direct medical cost 
paid by a patient was N229, 087.00, while the least total amount spent on treatment was N27, 590.00 with a range of N201, 
497 and interquartile range of N58, 186.00(Table 2). On the average, the direct medical cost paid from pocket by the 
patients for the treatment of Lassa fever was N86, 802.63 (Table 3).
Table 2: Total direct medical cost of treatment of Lassa fever
Median Q1 Q3 (Range)
Cost (N) 80,704 54,895 113,081 (27,590.00 - 229,087.00)
Q1- first quartile, Q3- third quartile, N- Naira
Table 3: Average direct medical cost of treatment of Lassa fever
Mean (Range)  
Average cost (N) 86,802.63 (27,590.00 - 229,087.00)
Pattern of cost of treatment of Lassa fever
In the treatment of Lassa fever at ISTH, the cost of investigation (confirmatory diagnostic test) and the cost of procuring 
the drug of choice effective against the virus, Ribavirin are subsidized for the patients. Overall, 61.80% of the total 
payments was subsidized, while what was paid by the patients (Out of pocket payment) was 38.20% of the total cost of 
treatment. Dialysis and oxygen accounted for the highest out-of-pocket payment, amounting to an average cost of N30, 000 
per patient with a maximum cost of N87, 600.00 and minimum cost of N1, 700.00. An average of N18, 300.00 and N18, 
250.00 was paid for investigations and hospital care respectively. Medications had an average cost of N12, 462.00 with the 
maximum paid by a patient being N40, 986.00 and the minimum N4, 016.00. The least (N5, 000) average out of pocket 
payment was spent on intravenous fluids (Table 4).
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Table 4: Pattern of cost for subsidized and unsubsidized treatment
Median Q1 Q3 Range Minimum Maximum
Hospital care (N) 18,250.00 8,950.00 24,725.00 51,450.00 3,800.00 55,250.00
Investigation
54,250.00 47,950.00 85,500.00 107,150.00 24,000.00 131,150.00Unsubsidized (N)
Subsidized    (N) 18,300.00 13,400.00 20,550.00 67,100.00 6,200.00 73,300.00
Medication
92,334.00 63,905.00 109,228.00 117,332.00 29,480.00 146,812.00Unsubsidized (N)
Subsidized     (N) 12,462.00 8,560.00 17,388.00 36,970.00 4,016.00 40,986.00
Intravenous Fluids (N) 5,000.00 3,600.00 6,300.00 7,120.00 1,580.00 8,700.00
Dialysis and Oxygen (N) 30,000.00 14,400.00 44,550.00 85,900.00 1,700.00 87,600.00
Others (N) 8,300.00 3905.00 11,435.00 29,650.00 1,250.00 30,900.00
Q1- first quartile, Q3- third quartile, N- Naira
Unsubsidized treatment cost
Medications accounted for the highest unsubsidized payment, (N92,334; 44.36%) as shown in Figure 2 above, with a 
maximum payment of N146,812.00 and a minimum of N29,480.00 (Table 4), together with  payments for investigations 
(26.06%) made up the bulk of the payments. Dialysis and oxygen came next in the unsubsidized cost pattern accounting for 
14.41%. Hospital care followed suit (8.77%) then payments for other items (3.99%) with the least payment been 
intravenous fluids (N5, 000; 2.4%) (Figure 1)
Figure 1: Pattern of cost of treatment (Unsubsidized)
Comparison of cost Subsidized and Unsubsidized treatment 
Only two sets of payments were subsidized, medications and investigations. For the medications, 86.5% of the payment 
was subsidized making an average of N79, 872.00, while patients had to pay 13.5% of the cost, which amounted to N12, 







Medications N92,334  
Others N8,300 
Dialysis and oxygen N30000
Hospital care  N18,250 
Investigations  N54,250 
IV fluid  N5,000 
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950 of the payments for investigations. The out of pocket payment for investigation amounted to an average of N18, 300 
which is 33.73% of the total cost of investigation.
When subsidized and unsubsidized payments are compared (figure 2). Medications accounting for the highest payments 
(44.36%) with an average of N92,334.00; then investigations (26.06%); dialysis and oxygen (14.41%), then hospital care 
(8.77%) and then others (3.99%) as illustrated in above. The pattern was however different for the subsidized payment with 
dialysis and oxygen accounting for the highest (32.5%) followed by investigations (19.82%) then closely followed by 
hospital care (19.77%). Payments made on medical supplies were next with 8.99%. Intravenous fluids accounts for the 
least (5.42%) payments both in the subsidized and unsubsidized payments.
Figure 2: Pattern of subsidized and unsubsidized treatment payment .
DISCUSSION
In this study, socio-demography revealed that  27(37%) of the 73 patients studied were aged 21-30 years with a mean age 
of 32.8 years which was in keeping with a similar study done in Northwest Nigeria (Sambo, et al., 2013). There was no 
significant sex predilection as male (50.07%) and female (49.3%) distributions were in almost same proportions unlike 
what was obtained in other similar studies done in Myanmar (Katzin, 2010) and other parts of Nigeria (Olalekan, 2013;
Sambo, et al., 2013). Expectedly, majority (83.6%) of the patients were Christians which is the predominant religion in 
Southern Nigeria. Lassa fever, like other viral haemorrhagic fevers is a disease which affects people across educational 
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primary level or had no formal education. This was akin to the finding of a study in Northwest Nigeria where Tertiary, 
Secondary and Primary levels represented 50%, 30%, 9.5% respectively (Sambo, et al., 2013)and another in India (Erika et 
al., 2012). Occupation is one of the risk factors in the epidemiology of Lassa fever. Some categories of workers are more 
likely to have occupational exposures by the nature of their job like the health workers when they treat infected patients. In 
this study however, 27.4% of the patients were students followed by business individuals making 26% of the cases with 
most of them being traders. Other occupations which included drivers, motorcyclists, hair stylists etc. accounted for 26% of 
the patients. The health workers in ISTH Irrua have over time learnt the art of effective personal protection and hence are 
less frequently affected. This may not be so with students especially those not from Edo State, who are yet to be sensitized 
on preventive measures and some lack good and proper food hygiene, stay in environment susceptible to rodent 
infestations. Traders are exposed when they handle contaminated food items like grains unprotected from rodents. 
With regards to treatment cost, the finding from this study is indicative that the treatment of Lassa fever can be an 
expensive experience particularly in present day economic recession for patients of lower socioeconomic status. The 
average patient’s expenditure on treatment was N86, 802.63 which is about 482.24% of the minimum wage (N18, 000.00) 
in Nigeria (Inalegwu, 2011). The median patient’s expenditure was N80, 704 with a maximum payment of N229, 087.00 
and a minimum of N27, 590.00. This high health care expenditure was similar to studies done on other infectious diseases 
in Malaysia (Muhammad et al., 2014) Myanmar (Inn et al., 2015), Uganda (Juliet et al., 2013)and in Nigeria (Olalekan et 
al., 2013; Enyi et al., 2015; Oforbuike et al., 2103 and Ogochukwu et al., 2012). Although a greater part of the expenditure 
is subsidized, patients still paid for some medications and investigations, IV fluids, oxygen, dialysis and hospital care 
including hospital registration which accounted for the high expenditure despite subsidy. Findings from this study though 
on the high may not be far from what is obtainable in other parts of the country. This is similar to ratios obtained in multi-
country analysis in Africa (Mclntyre et al., 2001; Xu et al., 2003; Cashin et al., 2010). The wide range between the 
maximum and minimum total cost of treatment is due to factors which include; length of hospital stay, this is a strong 
determining factor as the cost of hospital care, utilities and medical supplies, repeat investigations and continuous 
medication all affected the cost of treatment due to prolong hospital stay. Severity of the disease significantly affected the 
duration of hospital stay. Death within a few days of diagnosis greatly reduced the cost of treatment compared to patients 
that spent an appreciable time on treatment. Another factor is weight of the patient; this was proportional to the dosage of 
ribavirin given and translated to an increased cost. Another determining factor is the use of oxygen and the need for 
dialysis which are both expensive utilities; these contributed a huge chunk to the cost of treatment and were not covered by 
the subsidy. This was in keeping with a similar study done in the United states with a range of US$ (4-430).
The finding that dialysis and oxygen, drug cost and investigations took about 65.82% of the treatment expenditure despite 
subsidy, means that even if user fees are waived for services like registration and consultation, most of the poor people 
would still have to bear a huge burden of the direct cost by buying drugs and paying for investigations themselves which 
could be catastrophic to the low income earners. 
The results are comparable to similar studies done on the pattern of cost of treatment of common ailments, with 
medications being the highest (Oforbuike et al., 2013; Ogochukwu et al., 2012; Katzin et al., 2010) as seen in the 
unsubsidized pattern of treatment taking 44.36% with investigations (26.06%) next to it, as seen in another study done on 
health expenditures, payment and coping mechanisms in Nigeria (Oforbuike et al., 2013). Investigations still came second 
in the treatment expenditure despite a 66.27% subsidy, while bulk of the expenditure paid on the subsidized treatment was 
on dialysis and oxygen. 21 patients received oxygen alone in the course of their treatment, 10 utilized dialysis alone and 11 
utilized dialysis and oxygen together in the course of their treatment. This ancillary treatment contributed significantly 
(32.5%) particularly to the subsidized payment as this area was not covered by the subsidy. The burden on medications was 
greatly reduced by the subsidy with an 86.5% reduction. In comparing the subsidized and unsubsidized payments, the cost 
of treatment without subsidy (average total cost N211, 284.00) was enormous as compared to the cost of treatment with 
subsidy (average total cost N80, 704.00) that is patients had to pay N130, 580 less of the cost of treatment, which is just 
38.2% as OOP of the total cost with a 61.80% subsidy in the median total payments. There was an 86.5% subsidy in the 
expenditure for medication and a 66.27% subsidy in expenditure for investigations. Despite the subsidy, most patients still 
had to pay a lot to access treatment. This was similar to studies done relating to subsidy in Bangladesh (Nadia et al., 2010) 
and Cambodia (Sokrin et al., 2008). The implication of a very high level of OOP money is that a significant proportion of 
the poor may be driven into destitution after paying for health care. A severe ill health that afflicts the breadwinner of the 
family may completely impoverish the family especially those who sell their labour on daily basis to provide food for their 
families. Even the non-poor may be impoverished by large random out-of-pocket payments arising from unanticipated ill 
health. 
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The economic development of any country is closely related to the health status of its population. As such, an efficient and 
equitable health care system that responds to the need of its people is an important instrument that can break the vicious 
circle of poverty and ill-health. In order for Nigeria to move towards sustainable health spending that will lead to a 
sustainable health outcome, there is the need for investments in the improvement of healthcare with urgent need for a 
substantial increase in health sector investment to expand access to preventive and curative health services. If this is 
achieved, more and more people will escape from poverty and their health burden reduced. 
LIMITATION
This study did not monetize the indirect cost caused by the illness, which reflect mainly productivity losses caused by the 
problem or diseases, borne by the individual, family, society, or by the employer of the patients in other words lost income 
because of not being able to work. Man-hour loss was not therefore computed. Also intangible costs which reflect the costs 
of pain, grief, suffering and loss of quality of life which could not be quantified directly in monetary terms were beyond the 
scope of this study. Duration of Hospital stay was a variable that could not be altered to standardize the treatment cost, 
death of patients influenced the individual cost, as well as need for special treatments also affected the individual cost.  
Finally, nonverbal mode of data collection was another limiting factor as National Health Insurance Scheme (NHIS) 
payments, grants and financial assistance could not be ascertained, hence all payments were generalized as out of pocket. 
CONCLUSION
In conclusion, the findings from this study showed that the median total patients expenditure was N80,704.00 with a 
maximum payment of N229,087.00 and a minimum of N27,590.00. Two patterns of cost was observed, medications being 
the highest with 44.36% with investigations (26.06%) next to it in the unsubsidized pattern of treatment, while in the 
subsidized treatment pattern, dialysis and oxygen accounted for most (32.5%) of the payments as these items were not 
covered by the subsidy. Only two aspects of the treatment were subsidized and they include medication with an 86.5% 
subsidy and investigations with a 66.27% subsidy.
RECOMMENDATIONS
In the long term, it is important to recognize that health and poverty are closely linked. Reducing the burden of Lassa fever
in Nigeria will help to contribute to the economic well-being of communities and poverty-reduction will be an essential 
input into improving health. National Lassa fever control programmes should be instituted in Nigeria with the need to 
recognize these links, and identify mechanisms for ensuring that the poorest have access to essential health interventions. 
Efforts to improve access to Lassa fever treatment should explicitly incorporate efforts to protect patients from high OOP 
expenditure. This call for provision of subsidies to enable the sectors reduce prices for medications, investigations, medical 
supplies etc. and put in place regulatory mechanisms to check excesses. 
Detection and tackling of the menace of Lassa fever, thus eliminate the burden of treatment and care. Government should 
therefore focus on research that will be aimed at tackling the disease and prevention and also creating public awareness 
about the disease spread. 
Roles of the government in the health sector must be redefined and sharpened. Financial provisions should be made for the 
poor and vulnerable groups in the form of direct payments, subsidies, paying for insurance contributions or any other 
methods. Similarly, there is the need for expansion of social health insurance through the National Health Insurance 
Scheme (NHIS) to cover the informal sector as a means of increasing resources for health thereby ensuring universal 
access to care and providing financial protection to the poor and vulnerable. 
Creating an enabling environment for public/private partnership and encouraging the NGO's and philanthropists. Hence, 
any government policy that will offer free drugs, more drug subsidies other that ribavirin, vouchers and duty waivers (for 
those that want to import drugs) will tackle the financial burden of health cost. The policy may encourage drug production 
by local manufacturers by offering loans and tax cuts thereby driving down the cost of these drugs. In the interest of 
ensuring access for all, creative ways of making medicines available at affordable prices among the private providers has 
the potential to reduce the burden that results from OOP expenditure, especially on medicine. The high expenditure 
incurred on drugs alone highlights the need for expediting pro-poor interventions like exemptions and waivers aimed at 
improving access to health care for the vulnerable poor and other victims. The hospital should be encouraged to prioritize 
the management of Lassa fever, training of staff in the department of preventive medicine to create awareness to the public 
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on the need to prevent the spread of the disease. Also social works department of the hospital should prioritize welfare for 
Lassa fever prevention. 
Individuals should be encouraged to adhere strictly to the prevention guidelines on Lassa fever, practice good personal and 
environmental hygiene. They should have the need for early consultation to the health facilities for prompt diagnosis 
whenever the individual falls ill. There is need for the community to be educated on the causative agents, mode of 
transmission of Lassa fever and control of rats. There should be education on healthy cultural practices to avoid eating the 
rodents as delicacies and also prevention of contacts with rats and rat droppings. In addition health education to the 
community on good environmental hygiene and early recognition of the signs and prompt transfer of individuals with 
symptoms and signs of Lassa fever to the health faculty is recommended.  
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